It has been clearly documented that outpatient parenteral antibiotic therap
y (OPAT) saves money compared with hospital care for patients who need intr
avenous antimicrobial therapy. The reduced expenses come primarily from sav
ings in facility and hospital staffing costs. In addition to shortening hos
pital stay, OPAT programmes can be developed so that hospital care is avoid
ed altogether. However, even with the clear potential for savings, to have
a successful programme it is necessary to align the interests of the payers
, the physicians, the administrators and the patients.
The cost of OPAT programmes can also be reduced through patient evaluation
and careful selection of the appropriate delivery model, antibiotic, dosage
intervals and infusion technology. The fact that antibiotics such as ceftr
iaxone, the aminoglycosides and vancomycin can be given once daily in the e
lderly offers particular advantages in terms of convenience as well as cost
.
In order to achieve cost savings, managed carl will increasingly rely on ho
me and outpatient therapy. This pressure will need to be counterbalanced by
quality assurance programmes and outcomes measurements.